N6022 is primarily used as a selective antagonist for the P2X7 receptor, which plays a key role in inflammation and immune response. It is widely applied in research settings to study inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and neuroinflammatory conditions like Alzheimer's and multiple sclerosis. Due to its ability to inhibit ATP-mediated activation of the P2X7 receptor, N6022 helps reduce the release of pro-inflammatory cytokines, particularly IL-1β, making it a valuable tool in exploring therapeutic pathways for chronic inflammatory and autoimmune disorders. It is also used in neuroscience research to investigate the role of purinergic signaling in pain perception and neurodegeneration. Its selectivity and potency make it suitable for in vitro and in vivo studies aimed at validating P2X7 as a drug target.